FiercePharmaOriginal article
{"a":[{"_":"Boosted by CMS settlement, Incyte expects Opzelura to cross $1B in 2026","$":{"href":"/pharma/boosted-cms-settlement-incyte-expects-opzelura-cross-1b-2026","hreflang":"en"}}]}
RegulatoryapprovedOpzeluraPositive
AI Analysis
Summary
Incyte's Opzelura cream secured a favorable CMS settlement, positioning the drug to reach blockbuster status ($1B in revenue) ahead of schedule in 2026.
Financial Highlights
Revenue
$1B
Guidance
Expected to cross $1B in 2026
Outcome Details
CMS settlement favorable regulatory resolution
Importance:7/10
Sentiment:
0.80
CMS settlementRegulatory approvalBlockbuster potentialRevenue milestone
Related Companies
Read the original article
Published by FiercePharma on July 29, 2026 9:58 AM